Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Anxiolytic Drugs: Benzodiazepines and Buspirone01:29

Anxiolytic Drugs: Benzodiazepines and Buspirone

Benzodiazepines are a class of anxiolytic drugs known for their rapid efficacy and high therapeutic-to-lethal dose ratio, but with a potential risk of drug dependence. These drugs are lipophilic, allowing for rapid absorption after oral administration, eventually reaching the central nervous system (CNS). Once in the CNS, benzodiazepines bind to the allosteric site of the GABAA receptor. This binding enhances the inhibitory effects of the neurotransmitter GABA. By doing so, they prevent...
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Role for GABA<sub>A</sub> Receptor β3 Subunits in Mediating Harmaline Tremor Suppression by Alcohol: Implications for Essential Tremor Therapy.

Tremor and other hyperkinetic movements (New York, N.Y.)·2024
Same author

Search for Novel Therapies for Essential Tremor Based on Positive Modulation of α6-Containing GABA<sub>A</sub> Receptors.

Tremor and other hyperkinetic movements (New York, N.Y.)·2023
Same author

Alcohol and Ganaxolone Suppress Tremor via Extra-Synaptic GABA<sub>A</sub> Receptors in the Harmaline Model of Essential Tremor.

Tremor and other hyperkinetic movements (New York, N.Y.)·2023
Same author

Is the inferior olive central to essential tremor? Yes.

International review of neurobiology·2022
Same author

A Phase 2 Proof-of-Concept, Randomized, Placebo-Controlled Trial of CX-8998 in Essential Tremor.

Movement disorders : official journal of the Movement Disorder Society·2021
Same author

Increased Purkinje Cell Complex Spike and Deep Cerebellar Nucleus Synchrony as a Potential Basis for Syndromic Essential Tremor. A Review and Synthesis of the Literature.

Cerebellum (London, England)·2020

Related Experiment Video

Updated: Jun 26, 2026

MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor
05:54

MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor

Published on: December 13, 2017

Zonisamide for essential tremor: an evaluator-blinded study.

Adrian Handforth1, Fredricka C Martin, Gail A Kang

  • 1Department of Neurology, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California 90073, USA. charles.handforth@med.va.gov

Movement Disorders : Official Journal of the Movement Disorder Society
|January 2, 2009
PubMed
Summary

Zonisamide effectively reduced essential tremor in a 12-week trial. Doses around 200-250 mg daily showed benefits, while 300 mg/day increased adverse effects like somnolence and imbalance.

More Related Videos

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale
07:35

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

Related Experiment Videos

Last Updated: Jun 26, 2026

MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor
05:54

MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor

Published on: December 13, 2017

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale
07:35

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

Area of Science:

  • Neurology
  • Clinical Pharmacology

Background:

  • Essential tremor is a common neurological disorder.
  • Current treatments for essential tremor have limitations.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of zonisamide for treating moderate to severe upper limb essential tremor.

Main Methods:

  • An evaluator-blinded, open-treatment trial involving subjects with essential tremor.
  • Zonisamide was titrated up to 300 mg/day, with adjustments based on symptoms.
  • Efficacy was assessed using videotaped/drawing tremor scores and functional disability ratings.
  • A 12-week extension phase was included.

Main Results:

  • Significant reductions in tremor scores were observed at both treatment and extension visits (P < 0.00001).
  • Mean effective doses were 252 mg/day at treatment and 225 mg/day at extension.
  • Zonisamide 200 mg/day was superior to 100 mg/day, but 300 mg/day offered no additional benefit and increased adverse events.

Conclusions:

  • Zonisamide demonstrates efficacy in reducing essential tremor.
  • Optimal dosing appears to be around 200-250 mg/day, with higher doses associated with increased adverse symptoms.
  • Further placebo-controlled trials are recommended to confirm these findings.